Kiran Mazumdar-Shaw, Biocon executive chair (Samyukta Lakshmi/Bloomberg via Getty Images)
February 28, 2022 06:54 AM EST
Deals

Biosim­i­lars unite: Look­ing for com­mer­cial con­sol­i­da­tion, Bio­con buys out long­time part­ner Vi­a­tris for $3.3B

Amber Tong

Turn­ing a years-long part­ner­ship in­to own­er­ship, Bio­con is shelling out $3.335 bil­lion to buy out Vi­a­tris’ biosim­i­lars busi­ness.

Re­ports first emerged weeks ago about plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times